Detalles de la búsqueda
1.
Clinical review considerations of class I PI3K inhibitors in hematolymphatic malignancies by Center for Drug Evaluation.
Chin J Cancer Res
; 34(4): 415-421, 2022 Aug 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-36199534
2.
RNA N-6-methyladenosine enzymes and resistance of cancer cells to chemotherapy and radiotherapy.
Epigenomics
; 12(9): 801-809, 2020 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-32515221
3.
The relationship between pneumonitis and programmed cell death-1/programmed cell death ligand 1 inhibitors among cancer patients: A systematic review and meta-analysis.
Medicine (Baltimore)
; 99(41): e22567, 2020 Oct 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-33031304
4.
The Association Between the Incidence Risk of Peripheral Neuropathy and PD-1/PD-L1 Inhibitors in the Treatment for Solid Tumor Patients: A Systematic Review and Meta-Analysis.
Front Oncol
; 9: 866, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-31552184
5.
Criteria and regulatory considerations for the conditional approval of innovative antitumor drugs in China: from the perspective of clinical reviewers.
Cancer Commun (Lond)
; 43(2): 171-176, 2023 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-36683350
6.
[Advances in the Research of the Regulation of Chinese Traditional Medicine Monomer and Its Derivatives on Autophagy in Non-small Cell Lung Cancer].
Zhongguo Fei Ai Za Zhi
; 20(3): 205-212, 2017 Mar 20.
Artículo
en Zh
| MEDLINE | ID: mdl-28302224
Resultados
1 -
6
de 6
1
Próxima >
>>